AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

Cited by (339)

Items 101–200 of 339

1. AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer
   Marie-Anne Goyette, Rebecca Cusseddu, Islam E. Elkholi, Afnan Abu-Thuraia, Nehmé El-Hachem, Benjamin Haibe‐Kains, Jean‐Philippe Gratton, Jean‐François Côté · 2019 · Oncotarget
2. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
   Rafael Rosell, Andrés Felipe Cardona, Oscar G. Arrieta, Andrés Aguilar, Masaoki Ito, Carlos Pedraz‐Valdunciel, Jordi Codony‐Servat, Mariacarmela Santarpía · 2021 · British Journal of Cancer
3. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers
   Francesca Zammarchi, Karin EG. Havenith, Simon Chivers, Paul Hogg, Francois Bertelli, Peter Tyrer, Narinder Janghra, Halla W. Reinert, John Anthony Hartley, Patrick H. van Berkel · 2022 · Molecular Cancer Therapeutics
4. Axl Receptor Axis: A New Therapeutic Target in Lung Cancer
   Pavel A. Levin, Rolf A. Brekken, Lauren A. Byers, John Victor Heymach, David E. Gerber · 2016 · Journal of Thoracic Oncology
5. Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
   Alexandre Bertucci, François Bertucci, Anthony Gonçalvès · 2023 · Cancers
6. Gas6/AXL pathway: immunological landscape and therapeutic potential
   Xiaoqian Zhai, Dan Pu, Ru-Lan Wang, Jiabi Zhang, Yiyun Lin, Yuqing Wang, Ni Zhai, Xuan Peng, Qinghua Zhou, Lu Li · 2023 · Frontiers in Oncology
7. Impact of Expression of Vimentin and Axl in Breast Cancer
   Kimihiro Tanaka, Eriko Tokunaga, Yuka Inoue, Nami Yamashita, Hiroshi Saeki, Shinji Okano, Hiroyuki Kitao, Eiji Oki, Yoshinao Oda, Yoshihiko Maehara · 2016 · Clinical Breast Cancer
8. The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy
   Seyed Alireza Javadinia, Soodabeh Shahidsales, Azar Fanipakdel, Asma Mostafapour, Mona Joudi‐Mashhad, Gordon A. Ferns, Amir Avan · 2019 · Current Pharmaceutical Design
9. PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications
   Francisco Aguayo, Francisco Pérez-Domínguez, Julio César Osorio, Carolina Oliva G, Gloria M. Calaf · 2023 · Biology
10. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
    Toni Michel Brand, Mari Iida, Kelsey L. Corrigan, Cara M. Braverman, John P. Coan, Bailey G. Flanigan, Andrew P. Stein, Ravi Salgia, Jana Rolff, Randall J. Kimple et al. · 2017 · Science Signaling · Retracted
11. Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer
    Toni Michel Brand, Stefan Hartmann, Neil E. Bhola, Hua Li, Yan Zeng, Rachel A. O’Keefe, Max V. Ranall, Sourav Bandyopadhyay, Margaret Soucheray, Nevan J. Krogan et al. · 2018 · Cancer Research
12. Personalized and targeted therapy of esophageal squamous cell carcinoma: an update
    Yongjing Liu, Zhaohui Xiong, Andrea Beasley, Thomas Anthony D’Amico, Xiaoxin Luke Chen · 2016 · Annals of the New York Academy of Sciences
13. Function of Axl receptor tyrosine kinase in non-small cell lung cancer (Review)
    Guoan Zhang, Meng Wang, Hongli Zhao, Wen Cui · 2017 · Oncology Letters
14. PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment
    Jia-jie Shi, Hui Xing, Yuxiang Wang, Xi Zhang, Qimin Zhan, Meiyu Geng, Jian Ding, Linghua Meng · 2019 · Cancer Letters
15. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers
    Komal L. Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid M. Aljumaily et al. · 2020 · Clinical Cancer Research
16. CD44/HA signaling mediates acquired resistance to a PI3Kα inhibitor
    Cuixia Yang, Yumeng Sheng, Xiaoxing Shi, Yi‐Wen Liu, Yiqing He, Yan Du, Guoliang Zhang, Feng Gao · 2020 · Cell Death and Disease
17. Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer
    Jian Wu, Hongqiang Qin, Ting Li, Kai Cheng, Jiaqiang Dong, Miaomiao Tian, Na Chai, Hao Guo, Jinjing Li, Xin Yu You et al. · 2016 · Oncotarget
18. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL
    Lorena Fontán, Rebecca Goldstein, Gabriella Casalena, Matthew Durant, Matt R. Teater, Jimmy Wilson, Jude M. Phillip, Min Xia, Shivem B. Shah, Ilkay Us et al. · 2021 · Blood
19. Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation
    Ryan E. Henry, Evan Barry, Lillian Castriotta, Brendon Ladd, Aleksandra A. Markovets, Garry J. Beran, Yongxin Ren, Feng Zhou, Ammar Adam, Michael J. Zinda et al. · 2016 · Oncotarget
20. MicroRNA‐139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL
    Robert K. Nam, Tania Benatar, Christopher J. D. Wallis, Elizabeth Kobylecky, Yutaka Amemiya, Christopher Sherman, Arun K. Seth · 2019 · The Prostate
21. Gene of the month: Axl
    Matthew Brown, James R. Black, Rohini Sharma, Justin Stebbing, David James Pinato · 2016 · Journal of Clinical Pathology
22. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer
    Jane Antony, Elisa Zanini, Zoe Kelly, Tuan Zea Tan, Evdoxia Karali, Mohammad N. Alomary, Youngrock Jung, Katherine Nixon, Paula Cunnea, Christina Fotopoulou et al. · 2018 · EMBO Reports
23. Delineating the molecular mechanisms of tamoxifen’s oncolytic actions in estrogen receptor-negative cancers
    Daniel P. Radin, Parth Patel · 2016 · European Journal of Pharmacology
24. Exploiting receptor tyrosine kinase co-activation for cancer therapy
    Aik Choon Tan, Simon Vyse, Paul H. Huang · 2016 · Drug Discovery Today
25. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR
    Shuai Zhao, Yang Cao, Shibo Liu, Xu-an Wang, Runfa Bao, Yijun Shu, Yunping Hu, Yi‐Jian Zhang, Lin Jiang, Fei Zhang et al. · 2016 · Journal of Experimental & Clinical Cancer Research
26. The prognostic role of Gas6/Axl axis in solid malignancies: a meta-analysis and literature review
    Sheng Zhang, Xiang Shang Xu, Jie Xi Yang, Jian Guo, Teng Fei Chao, Yixin Tong · 2018 · OncoTargets and Therapy
27. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
    Ofra Novoplansky, Matthew G. Fury, Manu Prasad, Ksenia M. Yegodayev, Jonathan Zorea, Limor Cohen, Raphael Pelossof, Liz Cohen, Nora Katabi, Fabiola Cecchi et al. · 2019 · International Journal of Cancer
28. Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
    Dan Yan, Henry Shelton Earp, Deborah DeRyckere, Douglas K. Graham · 2021 · Cancers
29. Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA - and HRAS -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
    Alison Elizabeth Smith, Stacia Chan, Zhiyong Wang, Asako McCloskey, Quinn Reilly, Jayden Z. Wang, Hetika Vora Patel, Keiichi Koshizuka, Harris S. Soifer, Linda V. Kessler et al. · 2023 · Cancer Research
30. A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Xin Peng, Xin Huang, Talal Ben Lulu, Wenqing Jia, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Xi Chen, Shanshan Liu et al. · 2024 · Molecular Cancer
31. TAM receptor signaling in development
    Tal Burstyn‐Cohen · 2017 · The International Journal of Developmental Biology
32. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer
    Marguerite L. Palisoul, Jeanne M. Quinn, Emily J. Schepers, Ian S. Hagemann, Lei Guo, Kelsey Reger, Andrea R. Hagemann, Carolyn Kay McCourt, Premal H. Thaker, Matthew A. Powell et al. · 2017 · Molecular Cancer Therapeutics
33. Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips
    Qiang Tong, Xiaolong Wang, Shengbao Li, Gong‐Li Yang, Shu Jin, Zi-ye Gao, Xiaobo Liu · 2018 · OncoTargets and Therapy
34. A pathway map of AXL receptor-mediated signaling network
    Shobha Dagamajalu, Rex Devasahayam Arokia Balaya, Akhina Palollathil, Rohan Shetty, Guruprasad Bhat, Lydia W.T. Cheung, Thottethodi Subrahmanya Keshava Prasad · 2020 · Journal of Cell Communication and Signaling
35. The functional roles of long noncoding RNA DANCR in Human Cancers
    Lei Pan, Xiudi Xiao, Yuan Zhao, Liang Yin, Min Fu, Xu Zhang, Pengcheng Jiang · 2020 · Journal of Cancer
36. Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas
    Joanna M. Janus, Ryan F.L. O’Shaughnessy, Catherine A Harwood, Tania Maffucci · 2017 · Cancers
37. AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
    Siyang Yan, Niels Vandewalle, Nathan De Beule, Sylvia Faict, Ken Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Kim De Veirman · 2019 · Cancers
38. Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition
    Maria Dermit, Pedro Casado, Vinothini Rajeeve, Edmund H. Wilkes, Daniel E. Foxler, Hayley Campbell, Susan E. Critchlow, Tyson V. Sharp, John G. Gribben, Robert John Unwin et al. · 2016 · Oncogene
39. AXL: shapers of tumor progression and immunosuppressive microenvironments
    Yihui Liu, Lei Xu, Yuanyao Dou, Yong He · 2025 · Molecular Cancer
40. Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas
    Tsun-Wen Yao, Jie Zhang, Michael Prados, William A. Weiss, Charles David James, Theodore P. Nicolaides · 2016 · Oncotarget
41. Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR/EMT pathway and stimulates p53 for TKI sensitization in NSCLC
    Dhananjay Suresh, Ajit P. Zambre, S. Mukherjee, Shreya Ghoshdastidar, Yuexu Jiang, Trupti Joshi, Anandhi Upendran, Raghuraman Kannan · 2019 · Nanomedicine Nanotechnology Biology and Medicine
42. Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer
    Michelle J. Lee, Nan Jin, Jennifer Rubin Grandis, Daniel E. Johnson · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
43. Four PTEN ‐targeting co‐expressed mi RNA s and ACTN 4‐ targeting mi R ‐548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue
    Ilyes Berania, Guillaume B. Cardin, Isabelle Clément, Louis Guertin, Tareck Ayad, Éric Bissada, Phuc Félix Nguyen‐Tan, Édith Filion, Julie M. Guilmette, Olguta Gologan et al. · 2017 · International Journal of Cancer
44. AXL is a marker for epithelial‑mesenchymal transition in esophageal squamous cell carcinoma
    Guoan Zhang, Xia Kong, Meng Wang, Hongli Zhao, Sha Han, Ronghang Hu, Jian An Huang, Wen Cui · 2017 · Oncology Letters
45. TAM kinase inhibition and immune checkpoint blockade– a winning combination in cancer treatment?
    Pavlos Msaouel, Giannicola Genovese, Jianjun Gao, Suvajit Sen, Nizar M. Tannir · 2020 · Expert Opinion on Therapeutic Targets
46. Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
    Akira Ooki, Hiroki Osumi, Keisho Chìn, Masayuki Watanabe, Kensei Yamaguchi · 2023 · Therapeutic Advances in Medical Oncology
47. Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells
    Pol Giménez‐Xavier, Eva Pros, Ester Bonastre, Sebastián Morán, Ana Aza, Osvaldo Graña‐Castro, Gonzalo Goméz-López, Sophia V. Derdak, Marc Dabad, Anna Esteve‐Codina et al. · 2017 · Molecular Cancer Therapeutics
48. Head and neck squamous cell carcinoma
    2020 · Nature Reviews Disease Primers
49. Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia
    Hongqi Liu, Xizhi Feng, Kelli N. Ennis, Catherine A. Behrmann, P.N. Sarma, Tony T. Jiang, Satoshi Kofuji, Liang Niu, Yiwen Stratton, Hala Elnakat Thomas et al. · 2017 · Cell Reports
50. MiR-34a suppresses HNSCC growth through modulating cell cycle arrest and senescence
    Y Wang, J. Chen, Xinming Chen, F. Jiang, Yanan Sun, Yongcheng Pan, Wenyu Zhang, J. Zhang · 2017 · Neoplasma
51. YAP-driven malignant reprogramming of oral epithelial stem cells at single cell resolution
    Farhoud Faraji, Sydney I. Ramirez, Lauren M. Clubb, Kuniaki Sato, Valeria Burghi, Thomas S. Hoang, Adam Officer, Paola Y. Anguiano Quiroz, William M. G. Galloway, Zbigniew Mikulski et al. · 2025 · Nature Communications
52. TPL2 Is an Oncogenic Driver in Keratocanthoma and Squamous Cell Carcinoma
    Jun-Han Lee, Joo‐Hyung Lee, Sang Hyuk Lee, Sung‐Im Do, Sung Dae Cho, Ola Forslund, Kyung‐Soo Inn, Jeong-Sang Lee, Fang-Ming Deng, Jonathan Melamed et al. · 2016 · Cancer Research
53. CACNA1C-AS2 inhibits cell proliferation and suppresses cell migration and invasion via targeting FBXO45 and PI3K/AKT/mTOR pathways in glioma
    Tong Cao, Yue Cui, Yingying Wang, Linhui Wu, Ke Yu, Kai Chen, Jun Xia, Yuyun Li, Zhiwei Peter Wang, Jia Ma · 2022 · APOPTOSIS
54. Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences
    Yuhao Ye, Zhiyu Huang, Maoqing Zhang, Jiayue Li, Yiqiong Zhang, Chenghua Lou · 2023 · Biomedicine & Pharmacotherapy
55. AXL – a new player in resistance to HER2 blockade
    Anna Adam‐Artigues, Enrique Javier Arenas, Joaquı́n Arribas, Aleix Prat, Juan Miguel Cejalvo · 2023 · Cancer Treatment Reviews
56. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer
    Carmen Segrelles, David Contreras, Elena Navarro-Palomares, Carmen Gutiérrez‐Muñoz, Ramón García‐Escudero, Jesús María Paramio, Corina Lorz · 2018 · International Journal of Molecular Sciences
57. A controlled trial of HNSCC patient‐derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth
    Kara Marie Ruicci, Jalna Meens, Ren Sun, Giananthony Rizzo, Nicole C. Pinto, John Yoo, Kevin Fung, S. Danielle MacNeil, Joe S. Mymryk, John W. Barrett et al. · 2018 · International Journal of Cancer
58. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma
    Chengzhong Lin, Wei Lu, Zhenhu Ren, Yu Tang, Chunye Zhang, Rong Yang, Yiming Chen, Wei Cao, Lizhen Wang, Xu Wang et al. · 2016 · Cancer Letters
59. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma
    Jiayi Li, Chaoji Shi, Rong Zhou, Yong Han, Shengming Xu, Hailong Ma, Zhiyuan Zhang · 2020 · Cancer Science
60. Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor
    Hefeng Zhang, Peng Xia, Yang Dai, Jingwei Shao, Yinchun Ji, Yiming Sun, Bo Liu, Cheng Wei Xu, Jing Ai, Wenhu Duan · 2021 · Journal of Medicinal Chemistry
61. A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance
    Christopher E. Whitehead, Elizabeth K. Ziemke, Christy L. Frankowski-McGregor, Rachel A. Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Scott Kopetz et al. · 2024 · Nature Cancer
62. Targeting AXL in NSCLC
    Aubhishek Zaman, Trever Grant Bivona · 2021 · Lung Cancer Targets and Therapy
63. Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors
    Guus J.J.E. Heynen, Kamil Lisek, Regina Vogel, Annika Wulf-Goldenberg, Joshua Alcaniz, Élodie Montaudon, Elisabetta Marangoni, Walter Birchmeier · 2022 · Breast Cancer Research
64. Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas
    Jinlong Yin, Ji-Eun Jung, Sung Yong Choi, Sung Soo Kim, Young Taek Oh, Tae Hoon Kim, Eunji Choi, Sun Joo Lee, Hana Kim, Eun Ok Kim et al. · 2017 · Cancer Letters
65. Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
    Peiwen Yang, Yu‐Cheng Liu, Ya-Han Chang, Ching-Ching Lin, Pei‐Ming Huang, Kuo‐Tai Hua, Jang‐Ming Lee, Min‐Shu Hsieh · 2019 · Frontiers in Oncology
66. A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer
    Charlotte K. Milton, Annette J. Self, Paul Andrew Clarke, Udai Banerji, Federica Piccioni, David E. Root, Steven R. Whittaker · 2020 · Molecular Cancer Therapeutics
67. Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?
    Ian Dransfield, Sarah L. Farnworth · 2016 · Advances in experimental medicine and biology
68. Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer
    Xueling Liu, Yichao Xu, Yuxiang Wang, Yi Chen, Bo-bo Wang, Yi Wang, Yanhong Chen, Cun Tan, Lan-ding Hu, Qingyang Ma et al. · 2018 · Cancer Letters
69. Osimertinib and Dihydroartemisinin: A Novel Drug Combination Targeting Head and Neck Squamous Cell Carcinoma
    Imane CHAIB-OUKADOUR, Xueting Cai, David Lligé, Mariacarmela Santarpía, Eloisa Jantus Lewintre, Martyna Filipska, Carlos Pedraz‐Valdunciel, Jean Cui, Jie Yang, Jing Miao et al. · 2019 · Annals of Translational Medicine
70. Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors
    Macus Tien Kuo, Yan Long, Wen-Bin Tsai, Ying-Ying Li, Helen H.W. Chen, Lynn G. Feun, Niramol Savaraj · 2019 · Translational Oncology
71. Current landscape of targeted therapy in esophageal squamous cell carcinoma
    Amane Jubashi, Daisuke Kotani, Takashi Kojima, Naoko Takebe, Kohei Shitara · 2024 · Current Problems in Cancer
72. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma
    Ziyue Gu, Chaoji Shi, Jiayi Li, Yong Han, Bao Sun, Wuchang Zhang, Jing Wu, Guoyu Zhou, Weimin Ye, Jiang Li et al. · 2022 · BMC Medicine
73. HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma
    Kara D. Meister, Neal Rajan Godse, Nayel I. Khan, Matthew Louis Hedberg, Carolyn Kemp, Sucheta Kulkarni, Diego Alvarado, Theresa M. LaVallee, Seungwon Kim, Jennifer Rubin Grandis et al. · 2019 · Scientific Reports
74. Cancer Stem Cells in Oral Squamous Cell Carcinoma: A Narrative Review on Experimental Characteristics and Methodological Challenges
    Surendra Kumar Acharya, Saptarsi Shai, Yee Fan Choon, Indrayadi Gunardi, Firstine Kelsi Hartanto, Kathreena Kadir, Ajoy Roychoudhury, Rahmi Amtha, Vui King Vincent–Chong · 2024 · Biomedicines
75. Therapeutic implication of mTORC2 in oral squamous cell carcinoma
    Tomofumi Naruse, Souichi Yanamoto, Kohei Okuyama, Kentaro Yamashita, Keisuke Omori, Yuji Nakao, Shin‐ichi Yamada, Masahiro Umeda · 2016 · Oral Oncology
76. Weak power frequency magnetic fields induce microtubule cytoskeleton reorganization depending on the epidermal growth factor receptor and the calcium related signaling
    Xia Wu, Juan Du, Weitao Song, Mei-Ping Cao, Shude Chen, Ruohong Xia · 2018 · PLoS ONE
77. Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer
    Wenqiang Song, Laura C. Kim, Wei Han, Yuan Hou, Deanna N. Edwards, Shan Wang, Timothy S. Blackwell, Feixiong Cheng, Dana M. Brantley‐Sieders, Jin Chen · 2020 · Molecular Cancer Research
78. Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy
    Agata Mikołajczyk, Filip Mituła, Delfina Popiel, Bozena Kaminska, Maciej Wieczorek, Jerzy Pieczykolan · 2022 · Cancers
79. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib
    Arturo Simoni Nieves, Moshit Lindzen, Suvendu Giri, Nitin Gupta, Rishita Chatterjee, Boobash-Raj Selvadurai, Marieke Van Daele, Danielle Love, Yuya Haga, Donatella Romaniello et al. · 2024 · Cell Reports Medicine
80. Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization
    Julia B. Schüler, Cordula Tschuch, Kerstin Klingner, Daniel Bug, Anne-Lise Peille, Leanne de Koning, Eva Oswald, Hagen Klett, Wolfgang Sommergruber · 2019 · Cells
81. Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
    Lu Liu, Chung Hoow Kok, Verity A Saunders, Jueqiong Wang, Jennifer McLean, Timothy P. Hughes, Deborah L. White · 2018 · Oncotarget
82. Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment
    Federico Pedicona, Pedro Casado, Maruan Hijazi, John G. Gribben, Kevin Rouault‐Pierre, Pedro R. Cutillas · 2022 · Science Signaling
83. Development of PI3Kα inhibitors for tumor therapy
    Wenqing Jia, Shuyu Luo, Han Wen Guo, Dexin Kong · 2022 · Journal of Biomolecular Structure and Dynamics
84. Anti-EGFR conjugated nanoparticles to deliver Alpelisib as targeted therapy for head and neck cancer
    Alberto Juan, Carmen Segrelles, Almudena del Campo-Balguerías, Iván Bravo, Ignacio Silva, Jorge Peral, Alberto Ocaña, Pilar Clemente-Casares, Carlos Alonso‐Moreno, Corina Lorz · 2023 · Cancer Nanotechnology
85. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Albiruni Ryan Abdul Razak, Hung‐Ming Wang, Jang‐Yang Chang, Myung‐Ju Ahn, Pamela N. Münster, George R. Blumenschein, Benjamin Solomon, Wan‐Teck Lim, Ruey‐Long Hong, David G. Pfister et al. · 2023 · Targeted Oncology
86. Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS‐mutated ovarian cancer cells with high AXL expression
    Shiori Umemura, Yoshihiro Sowa, Yosuke Iizumi, Jo Kitawaki, Toshiyuki Sakai · 2020 · Cancer Science
87. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma
    Kara Marie Ruicci, Jalna Meens, Paul Plantinga, William Stecho, Nicole C. Pinto, John Yoo, Kevin Fung, S. Danielle MacNeil, Joe S. Mymryk, John W. Barrett et al. · 2020 · Journal of Experimental & Clinical Cancer Research
88. Impact of Tenascin-C on Radiotherapy in a Novel Syngeneic Oral Squamous Cell Carcinoma Model With Spontaneous Dissemination to the Lymph Nodes
    Caroline Spenlé, Thomas Loustau, Hélène Burckel, Gilles Riegel, Chérine Abou Fayçal, Chengbei Li, Alev Yilmaz, Luciana Petti, Fanny Steinbach, Constance Ahowesso et al. · 2021 · Frontiers in Immunology
89. Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations.
    S. Jagadeeshan, Manu Prasad, S. Ortiz-Cuàran, V. Grégoire, P. Saintigny, M. Elkabets · 2019 · Trends in Cancer
90. Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers
    Jane Antony, Elisa Zanini, James R. Birtley, Hani Gabra, Chiara Recchi · 2020 · Cancer Gene Therapy
91. Pharmacological and cell-specific genetic PI3Kα inhibition worsens cardiac remodeling after myocardial infarction
    Xueyi Chen, Pavel Zhabyeyev, Abul Kalam Azad, Bart Vanhaesebroeck, Chad Eric Grueter, Allan G. Murray, Zamaneh Kassiri, Gavin Y. Oudit · 2021 · Journal of Molecular and Cellular Cardiology
92. An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression
    Debjani Pal, Polona Šafarič Tepeš, Trine Lindsted, Ingrid Ibarra, Amaia Lujambio, Vilma Jiménez Sabinina, Şerif Şentürk, Madison A. Miller, Navya Korimerla, Jiahao Huang et al. · 2021 · eLife
93. A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia
    Ahmad Nasimian, Lina Al Ashiri, Mehreen Ahmed, Hongzhi Duan, Xiaoyue Zhang, Lars Rönnstrand, Julhash Uddin Kazi · 2023 · International Journal of Molecular Sciences
94. Targeting glutamine metabolism in PIK3CA mutant colorectal cancers
    Xiujing Feng, Yujun Hao, Zhenghe Wang · 2016 · Genes & Diseases
95. Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma
    Juan Carlos de Vicente, Ignacio Peña, Juan Pablo Rodrigo, Tania Rodríguez‐Santamarta, Paloma Lequerica–Fernández, Laura Suárez–Fernández, Eva Allonca, Juana Maria Garcia-Pedrero · 2017 · Head & Neck
96. Research Progress of Axl Inhibitors
    Zhigang Sun, Jianhua Liu, Jinmai Zhang, Yong Qian · 2019 · Current Topics in Medicinal Chemistry
97. The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance
    Kjersti T. Davidsen, Gry Sandvik Haaland, Maria K. Lie, James B. Lorens, Agnete S. T. Engelsen · 2017 · Springer eBooks
98. Efficient Arylation of 2,7-Naphthyridin-1(2H)-one with Diaryliodonium Salts and Discovery of a New Selective MET/AXL Kinase Inhibitor
    Mingshu Wang, Hong-Chuang Xu, Yi Gong, Ren‐Yu Qu, Linsheng Zhuo, Wei Huang · 2020 · ACS Combinatorial Science
99. Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells
    Yuxiang Wang, Xu Zhang, Qingyang Ma, Landian Hu, Xi Zhang, Yi Wang, Lan Xu, Chunhao Yang, Cun Tan, Xiangyin Kong et al. · 2021 · Cell Death and Disease
100. IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer
     Mai Badarni, Manu Prasad, Artemiy Golden, Baisali Bhattacharya, Liron Levin, Ksenia M. Yegodayev, Orr Dimitstein, Ben‐Zion Joshua, Limor Cohen, Ekaterina E. Khrameeva et al. · 2021 · Cancers